The critical role of ERK in death resistance and invasiveness of hypoxia-selected glioblastoma cells by Jee-Youn Kim et al.
BioMed CentralBMC Cancer
ssOpen AcceResearch article
The critical role of ERK in death resistance and invasiveness of 
hypoxia-selected glioblastoma cells
Jee-Youn Kim1,2, Yong-Jun Kim2, Sun Lee2 and Jae-Hoon Park*2
Address: 1Brain Korea 21 Project Center, College of Medicine, Kyung Hee University, Seoul 130-701, Korea and 2Department of Pathology and 
Medical Science and Engineering Research Center for Bioreaction to Reactive Oxygen Species, Kyung Hee University, Seoul, South Korea
Email: Jee-Youn Kim - falcon16@khu.ac.kr; Yong-Jun Kim - kyjaloge@khu.ac.kr; Sun Lee - leesun@khu.ac.kr; Jae-
Hoon Park* - jhpark@khu.ac.kr
* Corresponding author    
Abstract
Background: The rapid growth of tumor parenchyma leads to chronic hypoxia that can result in
the selection of cancer cells with a more aggressive behavior and death-resistant potential to
survive and proliferate. Thus, identifying the key molecules and molecular mechanisms responsible
for the phenotypic changes associated with chronic hypoxia has valuable implications for the
development of a therapeutic modality. The aim of this study was to identify the molecular basis of
the phenotypic changes triggered by chronic repeated hypoxia.
Methods: Hypoxia-resistant T98G (HRT98G) cells were selected by repeated exposure to
hypoxia and reoxygenation. Cell death rate was determined by the trypan blue exclusion method
and protein expression levels were examined by western blot analysis. The invasive phenotype of
the tumor cells was determined by the Matrigel invasion assay. Immunohistochemistry was
performed to analyze the expression of proteins in the brain tumor samples. The Student T-test
and Pearson Chi-Square test was used for statistical analyses.
Results: We demonstrate that chronic repeated hypoxic exposures cause T98G cells to survive
low oxygen tension. As compared with parent cells, hypoxia-selected T98G cells not only express
higher levels of anti-apoptotic proteins such as Bcl-2, Bcl-XL, and phosphorylated ERK, but they also
have a more invasive potential in Matrigel invasion chambers. Activation or suppression of ERK
pathways with a specific activator or inhibitor, respectively, indicates that ERK is a key molecule
responsible for death resistance under hypoxic conditions and a more invasive phenotype. Finally,
we show that the activation of ERK is more prominent in malignant glioblastomas exposed to
hypoxia than in low grade astrocytic glial tumors.
Conclusion: Our study suggests that activation of ERK plays a pivotal role in death resistance
under chronic hypoxia and phenotypic changes related to the invasive phenotype of HRT98G cells
compared to parent cells.
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Adequate supplies of oxygen and nutrients from the vas-
cular network are requisite for robust tumor growth. How-
ever, uncoordinated growth rates between the tumor
parenchyma and the vascular connective tissue expose
cancer cells to a hypoxic environment, thereby limiting
further growth of the tumor mass. Conversely, hypoxia
may select for cancer cells with an aggressive behavior
because tumor cells that can overcome the unfavorable
oxygen conditions will survive and proliferate [1-3].
Hypoxic selection may result in a poor response to treat-
ment, recurrence of cancer, and metastasis. Therefore,
investigation of the phenotypic changes induced by
chronic hypoxia and the underlying molecular mecha-
nisms is fundamental to develop appropriate and effective
cancer treatment modalities as well as to comprehend
tumor biology.
Cellular stresses such as hypoxia induce activation of
diverse signaling pathways, which allow cells to survive in
unfavorable conditions. Among the activated signaling
pathways, mitogen-activated protein kinases (MAPKs) are
early responders to hypoxic conditions [4]. MAPKs are ser-
ine/threonine kinases that regulate various cellular
responses such as proliferation, differentiation, and apop-
tosis [4,5]. The extracellular signal-regulated kinase, ERK,
a subfamily member of MAPKs, is a key molecule respon-
sible for survival under hypoxia [6,7]. ERKs induce
hypoxia inducible factor-1 (HIF-1), a master transactiva-
tor in hypoxic conditions, which in turn regulates tran-
scription of hypoxia-adaptive proteins such as VEGF,
erythropoietin, and Glut-1 [8-10]. However, while some
candidate proteins responsible for adaptation in hypoxia
are well characterized, the identity of proteins involved in
chronic hypoxia selection and death resistance are largely
unidentified.
This study was designed to identify the molecular basis of
phenotypic changes triggered by chronic hypoxia. By
establishing death-resistant cells selected by repeated epi-
sodes of exposing the T98G glioblastoma cell line
(HRT98G) to hypoxia and reoxygenation, we found that
ERK plays a pivotal role in hypoxia selection and resist-
ance. In addition, we show that high expression of phos-
phorylated ERK (p-ERK) is responsible for HRT98G cells
having a more invasive phenotype than the parent cells.
Together, our results suggest that ERK is a key molecule
involved in death resistance to chronic hypoxia.
Methods
Cell culture, hypoxic conditions, and cell death assay
The T98G glioblastoma cell line was obtained from the
American Type Culture Collection (Rockville, MD, USA)
and cultured in Dulbecco's modified Eagle's (DMEM)
supplemented with 10% fetal bovine serum. For hypoxic
condition, cells in a degassed medium were exposed to
0.5% O2 balanced with 5% CO2/94.5% N2 in a hypoxic
chamber (In vivo2, Ruskinn, UK), followed by incubation
in normal culture conditions for recovery. The cell death
rate was determined by the trypan blue exclusion method.
Antibodies and reagents
Antibodies used in this study were obtained from Cell Sig-
naling Technology (Beverley, MA, USA). Anti-HGTD-P
antibody was produced as previously described [11]. All
reagents were purchased from Sigma-Aldrich, Inc. (St.
Louis, MO, USA), unless otherwise specified.
Immunoblot analysis
Cells were harvested and suspended in lysis buffer con-
taining 10 mM Tris-HCl (pH 7.4), 1% NP-40, 0.1%
sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 0.5 mM phenylmethylsulfonyl fluo-
ride, 1.1 mM Na3VO4, and 10 mM NaF. Extracted proteins
were separated by SDS-PAGE on 12% polyacrylamide gels
and electrophoretically transferred onto nitrocellulose
membranes. Membranes were probed with primary anti-
body, and then incubated with horseradish peroxidase-
coupled secondary antibody. Detection was performed
with a chemiluminescence-based detection kit (Amer-
sham Pharmacia Biotech., UK).
Ras activity assay and determination of reactive oxygen 
species (ROS)
Ras activity was measured with a Ras activity assay kit
(Upstate, MA, USA) detecting Ras bound to the Ras-bind-
ing domain of Raf-1, as described previously [12]. For
determination of ROS, cells were suspended in PBS con-
taining 5 μM dichlorofluorescine diacetate (DCFH-DA),
followed by incubation at 37°C for 30 min. After washing
with PBS, cells were analyzed by cytomics FC500 using
CXP software (Beckman Coulter, CA, USA).
Knockdown of ERK
HRT98G cells were transfected with siRNA specific to ERK
(siERK) (Santa Cruz Biotech., CA) or control siRNA
(siControl) according to manufacturer's protocol. Knock-
down of the target gene was confirmed by immunoblot-
ting.
Invasion assay
Invasion assays were carried out using the cell invasion kit
(Chemicon, USA) according to the manufacturer's proto-
col. Briefly, 104 cells were plated on a Matrigel-coated
transwell invasion chamber with or without PD98059 or
phorbol myristate acetate (PMA), and incubated at 37°C
for 24 h. Non-invading cells were removed by wiping the
upper side of the membrane of the transwell. Invading
cells were fixed with methanol and stained with hematox-
ylin. Three independent invasion assays in triplicate werePage 2 of 9
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under a light microscope.
Tumor samples
The study was approved by the institutional review board
of Kyung-Hee University Hospital. Twenty cases of astro-
cytic glial tumor samples [7, World Health Organization
(WHO) grade I; 3, grade II; 3, grade III; 7, grade IV] were
obtained from the hospital. Tissue samples were fixed
with 10% phosphate-buffered formalin, embedded in
paraffin, and sectioned into sections of 4 μm thickness.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue sections were
deparaffinized, rehydrated, and washed twice for 5 min-
utes in wash buffer (50 mM Tris/HCl, pH 7.6, 50 mM
NaCl). Endogenous peroxidase was quenched with perox-
idase blocking solution (Dako, Carpinteria, CA) for 10
minutes. Slides were washed as before and then incubated
in blocking solution (Dako) for 1 hour. This was followed
by incubation with anti-p-ERK, (Cell Signaling Technol-
ogy) or anti-HGTD-P rabbit polyclonal antibody for 1
hour. The slides were washed twice and further incubated
with biotinylated secondary antibody and avidin-conju-
gated horseradish peroxidase. The slides were visualized
using the DAB substrate-chromogen system (Dako) and
counterstained with hematoxylin. Evaluation of immuno-
histochemical staining was performed by arbitrary quan-
titative scoring system. Fields with no positively-stained
cells were scored as 0. Fields with less than 25% posi-
tively-stained cells were scored as 1; fields with between
26 to 50% positively-stained cells were scored as 2; fields
with positively-stained areas between 51 to 75% were
scored as 3; and fields with a positively-stained area
greater than 76% were scored as 4. For each case, the mean
score (sum of scores for each field/fields counted) was cal-
culated.
Statistics
Statistical analyses were carried out using SPSS software,
version 13.0 (SPSS, Chicago, IL. USA). We applied the Stu-
dent T-test for invasion assay or the Pearson Chi-Square
test to assess the association between p-ERK expression
and tumor grade or HGTD-P expression in astrocytic glial
tumors. Differences with a p value < 0.05 were considered
statistically significant.
Results
Selection of death-resistant cells by repeated exposure to 
hypoxia
To select death-resistant clones of T98G cells induced by
hypoxia, we exposed cells to 0.5% O2 for 6 h and then
returned the cells to normal oxygen tension for recovery.
After 6 h of recovery time, detached dead cells were
removed and viable cells were further subjected to
repeated cycles of hypoxia-normoxia. Cell death rate was
determined following the recovery phase of each cycle. As
shown in Fig. 1A, more than 85% of cells died after the
first cycle, but less than 5% of cells died after 10 repeated
cycles. In parallel with cell death rates, caspase-3 and
PARP were cleaved after 6 h of hypoxic exposure in parent
cells, but not in HRT98G cells (Fig. 1B). Next, to deter-
mine whether death resistance of HRT98G cells is specific
to hypoxia or not, HRT98G cells were exposed to various
damaging stimuli including tumor necrosis factor (TNF)-
1α, H2O2, ultraviolet light (UV), and etoposide. As shown
Selection of HRT98G cells by repeated episodes of hypoxiaFigure 1
Selection of HRT98G cells by repeated episodes of 
hypoxia. (A) Cell death assay using the trypan blue exclu-
sion method was performed after the indicated cycles of 
repeated exposure to hypoxia and normoxia. (B) Immunob-
lot analysis for PARP and cleaved caspase-3 after the indi-
cated cycles. P, parent cells (C) Sensitivity of HRT98G cells 
to different types of cytotoxic stimuli. T98G and HRT98G 
cells were exposed to 20 ng TNF-α for 4 h, 100 μM H2O2 for 
24 h, 100 mJ/cm2 UV for 24 h, and 20 μM etoposide for 12 h. 
Cell death was determined by the trypan blue exclusion 
method.Page 3 of 9
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H2O2, UV, and etoposide. Together, our data shows that
repeated episodes of hypoxic and normoxic exposure
cause T98G cells to survive the low oxygen tension and
that the death resistance of HRT98G cells is dependent on
the type of injury.
Alterations of protein expression in death pathways and 
ROS
To gain insight into the death resistance mechanism of
HRT98G cells, we used immunoblot analysis to detect
alterations in expression of proteins involved in cell death
pathways, such as pro-apoptotic, anti-apoptotic, and sign-
aling proteins. Among the anti-apoptotic proteins, expres-
sion of Bcl-2 and Bcl-XL, both well-known and common
death inhibitor factors, was markedly increased in
HRT98G cells compared to parent control cells (Fig. 2A).
In contrast, we did not find any significant changes in the
expression levels of some other anti-apoptotic proteins,
including Bcl-w, Mcl-1, and DIVA (Fig 2A), and pro-apop-
totic proteins such as Bak, Bax, Bok, Bad, Bid Bik, Hrk, and
Bim (Fig. 2B) between parent cells and HRT98G cells.
Next, we examined the signal transducing proteins that
transmit death-inducing and death-inhibiting signals,
such as ERK, c-jun N-terminal kinase (JNK), and AMP-
activated protein kinase (AMPK). Of note, we found that
the p-ERK is markedly increased in HRT98G cells com-
pared to parental cells (Fig. 2C). To know the upstream
signals responsible for ERK activation in HRT98G cells,
we determined Ras activity and ROS level because it has
been known that ROS and Ras activation are the initial
steps for the activation of MAPK cascades in hypoxic sig-
nal transduction [13,14]. As shown in Fig. 3, Ras activity
and ROS level were significantly increased in HRT98G
cells compared to T98G cells, suggesting that they may be
the upstream activators of ERK pathway.
Difference in protein expression between parent T98G and HRT98G cellsFigu  2
Difference in protein expression between parent 
T98G and HRT98G cells. Proteins were extracted from 
T98G and HRT98G cells and immunoblots were performed 
on (A) anti-apoptotic Bcl-2 family proteins, (B) pro-apoptotic 
Bcl-2 family proteins, and (C) signaling molecules. Densito-
metric analysis was performed and data is presented as the 
ratio of protein levels of T98G to HRT98G cells. Represent-
ative immunoblots were shown in the right panels of the A, 
B, and C.
Determination of Ras activity and ROS level in HRT98G cellsFigu e 3
Determination of Ras activity and ROS level in 
HRT98G cells. (A) The Ras activity was assessed by precip-
itating GTP-bound active Ras with Raf-1 Ras binding domain-
agarose conjugate (Top panel). The lower panel demon-
strates that equal amounts of Ras were present. (B) The lev-
els of ROS was measured in T98G and HRT98G using 
DCFH-DA ROS-sensitive fluorescence dye.Page 4 of 9
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cells is independent of ERK pathway
Previously, it has been reported that the ERK activation
up-regulates the expression of Bcl-2 and Bcl-XL, thereby
preventing cell death at the mitochondrial level [15].
Therefore, to examine whether the up-regulation of Bcl-2
and Bcl-XL in HRT98G cells was affected by the ERK acti-
vation, HRT98G cells were treated with specific ERK
inhibitor PD98059 (IC50 ≈7 μM) or U0126 (IC50 ≈0.4
μg/ml), and then the expression levels of Bcl-2 and Bcl-XL
were determined by immunoblots. As shown in Fig. 4,
inhibition of ERK activation did not down-regulate the
expressions of Bcl-2 and Bcl-XL, suggesting that up-regula-
tion of Bcl-2 and Bcl-XL expression by repeated hypoxia
did not result from ERK activation.
Activation of ERK pathways in HRT98G
Given the higher expression of p-ERK in HRT98G cells, we
next investigated whether ERK activation is responsible
for the death resistance of these cells. HRT98G cells were
treated with PD98059 or U0126, and cells were then sub-
jected to 0.5% hypoxia for 6 h. As shown in Fig. 5A, sup-
pression of ERK activation by these specific inhibitors
restored the hypoxia sensitivity of HRT98G cells, suggest-
ing that activation of ERK is a key event responsible for the
death resistance of HRT98G cells. The critical role of ERK
in hypoxia resistance was reinforced by knockdown of
ERK using siRNA (siERK) (Fig. 5B). To confirm our results,
we treated T98G cells with the ERK pathway activator
PMA [16]. In addition, activation of ERK in T98G cells
diminished sensitivity to hypoxia to the level of HRT98G
cells (Fig. 3C). Together, our results suggest that ERK acti-
vation is mandatory for the hypoxia-induced death resist-
ance of HRT98G cells.
The effect of ERK activation on in vitro invasion
Invasive growth of tumors is one of the most important
hallmarks of malignancy [17,18]. Therefore, we examined
whether HRT98G cells are more invasive than their paren-
tal cells. Invasion assays were performed using Matrigel-
coated transwell invasion chambers, as shown in Fig. 6A,
and HRT98G cells were found to be more invasive than
Effects of ERK on the expression level of Bcl-2 and Bcl-XL in HGT98G cellsFigure 4
Effects of ERK on the expression level of Bcl-2 and 
Bcl-XL in HGT98G cells. HGT98G cells were treated with 
30 μM PD98059 (left panel) or 40 μg/ml U0126 (right panel), 
and the expression levels of Bcl-2 and Bcl-XL was determined 
by immunoblots.
Activation of ERK in HRT98G cells (A) HRT98G cells were pre-treated with the ERK inhibitor PD98059 or U0126 at the indicated c ncen ration and a trypan blue exclusion assay was p rformed after 6 h of ypoxiFigu  5
Activation of ERK in HRT98G cells (A) HRT98G cells 
were pre-treated with the ERK inhibitor PD98059 or 
U0126 at the indicated concentration and a trypan 
blue exclusion assay was performed after 6 h of 
hypoxia. Immunoblots for p-ERK and tubulin are shown in 
the upper panel. (B) HRT98G cells were transfected with the 
indicated concentration of siERK for 48 h and cell death 
assay was performed as described in A. Immunoblots for 
ERK and tubulin are shown in the upper panel. (C) T98G 
cells were treated with the ERK activator PMA at the indi-
cated concentration and cell death assay was performed as 
described in A. The immunoblots for p-ERK and tubulin are 
shown in the upper panel.Page 5 of 9
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responsible for the invasive phenotype of HRT98G cells,
we performed invasion assays with T98G and HRT98G
cells, untreated or treated with PD98059, siERK, or PMA.
Inactivation of ERK by PD98059 or siERK suppressed the
invasive potential of HRT98G cells (Fig. 6A). In contrast,
increased invasiveness was observed in PMA-treated ERK-
activated T98G cells (Fig. 6A). Representative images of
the invasion assay are shown in Fig. 6B. This result sug-
gests that activation of the ERK pathway is a key event
responsible for the aggressive behavior of HRT98G cells.
Activation of ERK in hypoxic tumor tissue
To confirm that ERK activation is important for the aggres-
sive behavior induced by chronic hypoxia, we examined
whether ERK is activated in the region of the tumor
exposed to hypoxia. To this end, 10 low- and high-grade
astrocytic glial tumors were immunohistochemically
stained for p-ERK and HGTD-P, marker proteins
expressed in hypoxia [11]. The expression of p-ERK was
correlated with tumor grade (Table 1). All high grade
tumors (grade III and IV) showed 3+ or 4+ expression of
p-ERK protein, whereas 70% of low grade tumors (grade I
and II) exhibited 1+ or 2+ expression of the protein (p =
0.006). The results for p-ERK expression were similar to
those for HGTD-P expression with statistical significance
(p = 0.027) (Table 2). Representative immunohistochem-
ical staining is shown in Fig. 7. These results suggest that
the ERK pathway is activated in tumor areas exposed to
hypoxia.
Discussion
The chronic hypoxia that results from the rapid growth of
tumor parenchyma can select for cancer cells with a more
aggressive behavior and a death-resistant phenotype.
Thus, identifying the key molecules responsible for these
phenotypic changes and their molecular mechanisms is
important to develop effective therapeutic modalities. The
aim of this study was to identify the molecular basis of the
phenotypic changes triggered by chronic repeatedActivation of ERK facilitates invasive growth of T98G cellsFigure 6
Activation of ERK facilitates invasive growth of T98G 
cells. (A) T98G and HRT98G cells, untreated or treated 
with 30 μM PD98059, 100 nM siERK, or 100 nM PMA, were 
plated in Matrigel-coated transwell chambers at 104 cells per 
well. After 24 h, the cells on the lower side of the chamber 
were fixed and stained with hematoxylin. The number of 
cells that invaded the Matrigel-coated transwell chamber was 
counted using a light field inverted microscope. The data is 
the results of three independent experiments in triplicate. An 
average of six fields of cells was counted under 100× magnifi-
cation. (*, #, †, ‡, P < 0.01). (B) Representative images of the 
in vitro invasion assay.
Representative hematoxylin and eosin (H&E) and immunohis-toch mical pictures of p-ERK and HGTD-P in low (grade II)- and high (grad  IV)- grade astrocytic glial tumorsFigure 7
Representative hematoxylin and eosin (H&E) and 
immunohistochemical pictures of p-ERK and HGTD-
P in low (grade II)- and high (grade IV)- grade astro-
cytic glial tumors.Page 6 of 9
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T98G cells after repeated episodes of hypoxia and nor-
moxia. Over 95% of HRT98G cells selected by more than
10 hypoxic cycles survived after 6 hours of hypoxia. How-
ever, death resistance was not specific for hypoxia only
because cells were also resistant to TNF-α-induced death.
This suggests that death resistance induced by repeated
hypoxic cycles results from a common downstream death
pathway. While up-regulation of death-inhibitory pro-
teins like Bcl-2 and Bcl-XL in HRT98G cells may support
this hypothesis, different sensitivities to other types of
injuries such as H2O2 and UV indicate that death resist-
ance cannot be solely explained by anti-apoptotic Bcl-2
family proteins. Previously, Dong and Wang [19] found
that immortalized rat kidney epithelial cells selected by
hypoxia were cross-resistant to the diverse apoptotic stim-
uli such as staurosporin, azide, and cis-platin, at the mito-
chondrial level by up-regulation of Bcl-XL, but not by Bcl-
2. Although this discrepancy in Bcl-2 expression involved
in death-resistant phenotypic changes may come from the
difference in cell types and cytotoxic stimuli used, further
studies are required for the explanation of the precise
molecular mechanisms. Nevertheless, our study on the
gene expression in hypoxia-selected cells showed that ERK
activation is crucial for the invasive potentials of selected
cells as well as death resistance.
ERK is activated by MAPK in response to growth stimuli
and involved in diverse cellular signaling pathways,
including pathways involved in survival and proliferation
[20,21]. Our results show that repeated exposure to
hypoxia-normoxia results in activated ERK pathways
through Ras activation. While there is accumulating evi-
dence that ERK activation induces cell proliferation and
inhibition of apoptosis, the signaling mechanism under-
lying ERK activation by repeated hypoxia-reoxygenation is
not clear. If the hypoxia-reoxygenation cycles are consid-
ered to be a type of oxidative stress on the cells, then ERK
might be activated via reactive oxygen species (ROS)-
dependent pathways, as shown in Fig 3. NADPH oxidase
activation and subsequent ROS generation shortly after
reoxygenation have been suggested to initiate ERK signal-
ing [22,23]. In support of this, Wang et. al. [24] and
Kumar et. al. [25] have reported that hypoxia/reoxygena-
tion or oxidative stress induces ERK activation, which is
required for the aggressive phenotype of prostatic cancer.
Astrocytic glial tumors, including low-grade (WHO grade
I and II) and high-grade astrocytoma (WHO grade III and
IV), are the most common tumors of glial cell origin
[26,27]. In our study, immunohistochemical staining of
astrocytic glial tumors showed that tumor cells with
aggressive and invasive behavior express higher levels of
p-ERK and HGTD-P than low-grade tumor tissues. These
data confirm the role of p-ERK in the chronic hypoxic-
induced aggressive cell phenotype.
We have shown that ERK activation influences the devel-
opment of an invasive phenotype. The generality of
increased invasiveness mediated by ERK activation is an
important question. In our system, we found that the
amount of matrix metalloproteinase-3 (MMP3) transcript
was significantly increased in HRT98G cells (data not
shown). MMP3 up-regulation by activated ERK may be
responsible for the invasiveness of HRT98G cells. In
future studies, we intend to investigate the role of signal-
ing pathways downstream of ERK in hypoxic cell death
resistance.
Conclusion
Collectively, we showed that repeated episodes of expo-
sure to hypoxia and normoxia change T98G cells to
HRT98G cells that have a more death-resistant and inva-
sive phenotype. As compared with parent cells, HRT98G
Table 1: Comparison of p-ERK expression with tumor grade in 
astrocytic glial tumors
WHO grade Expression of p-ERK (%)
1+ 2+ 3+ 4+
Low grade Grade I (n = 7) 2 (28) 3 (43) 2 (28) 0 (0)
Grade II (n = 3) 0 (25) 2 (50) 1 (25) 0 (0)
High grade Grade III (n = 3) 0 (0) 0 (0) 2 (67) 1 (33)
Grade IV (n = 7) 0 (0) 0 (0) 3 (43) 4 (57)
p = 0.006, analyzed by Pearson Chi-Square test.
Table 2: Comparison of p-ERK expression with HGTD-P expression in astrocytic glial tumors
Protein Expression of p-ERK (%)
Immunoreactivity 1+ (n = 2) 2+ (n = 5) 3+ (n = 8) 4+ (n = 5)
HGTD-P 1+ (n = 3) 0 (0) 3 (100) 0 (0) 0 (0)
2+ (n = 7) 2 (28.6) 1 (14.3) 4 (57.1) 0 (0)
3+ (n = 6) 0 (0) 1 (16.7) 2 (33.3) 3 (50.0)
4+ (n = 4) 0 (0) 0 (0) 2 (50.0) 2 (50.0)
p = 0.027, analyzed by Pearson Chi-Square test.Page 7 of 9
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BMC Cancer 2009, 9:27 http://www.biomedcentral.com/1471-2407/9/27cells express higher levels of anti-apoptotic proteins such
as bcl-2, Bcl-XL, and p-ERK. Activation or suppression of
ERK pathways with a specific activator or inhibitor,
respectively, demonstrates that ERK is a key molecule
responsible for the death resistance associated with
hypoxia and a more invasive phenotype. Finally, we show
that the activation of ERK is more prominent in high
grade astrocytic glial tumors exposed to hypoxia than in
low grade tumors. Our results may be helpful in develop-
ing appropriate and effective cancer treatment modalities.
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